<Anchor>



AstraZeneca vaccine, which had been discontinued due to controversy over side effects, will also resume from tomorrow (12th).

However, I decided to exclude those under the age of 30.

Since there is more concern about side effects than preventive effects, other vaccines have to be used, but when and how to obtain alternative vaccines has not been decided yet.



Reporter Jang Se-man will explain.



<Reporter>



To decide whether to continue using the AstraZeneca vaccine, health authorities analyzed the benefits and risks of getting the vaccine by age group, as did the European Medicines Agency.



It is assumed that the number of confirmed cases per day is up to an average of 1,200 per day for three months, and the entire population has received the AstraZeneca vaccine.



In their 30s, the effect of preventing corona death was 6.9, while the number of deaths from blood clots was predicted to be 4.



The vaccination is more profitable than the actual one.



The same was true for people in their 40s and older, with the higher the age group, the greater the benefit than the risk.



[Jeong Jae-hoon/Professor of Vaccination Advisory Group: Those over 50 years of age have been found to have more than 10 times the benefit, and over 80 years of age, it will be 690 times more.]



On the other hand, in their twenties, the risk of dying from blood clots is rather than preventing death

.

I found this to be bigger.



Accordingly, the health authorities decided to resume the AstraZeneca vaccination, which had been discontinued for under 60 years of age for four days, from tomorrow, but a different vaccine was used for those under 30 years of age.



The problem is that there is no vaccine plan for 640,000 people under the age of 30 who will be vaccinated against AstraZeneca in the second quarter.



[Eun-kyung Jung/Director of the Korea Disease Control Center: Those under the age of 30 need to get another vaccine, and a plan for which vaccine to put at what time should be supplemented.]




Even under the age of 30, out of the 135,000 people who completed the first dose of the AstraZeneca vaccine, those who did not have side effects of blood clots were given a second dose of the same vaccine.